Top ▲

Chronic idiopathic urticaria

Disease ID:1232
Name:Chronic idiopathic urticaria
Associated with:0 target
2 immuno-relevant ligands
A condition characterised by frequent and recurrent wheals and itching with no known cause.


No target related data available for Chronic idiopathic urticaria


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: An anti-IgE therapy approved to treat antihistamine-resistant chronic idiopathic urticaria .
Clinical Use: Used to treat moderate to severe IgE-mediated (i.e. allergy triggered) persistent asthma (US) or severe asthma (EU) [4], in adults and children over 12 years old, inadequately controlled by inhaled corticosteroid treatment. In 2014 the US FDA approved use of this drug for the treatment of chronic idiopathic urticaria (CIU, a.k.a. chronic spontaneous urticaria) which is unresponsive to treatment with anti-histamine H1 receptor drugs.
In July 2016, the FDA expanded asthma approval to include children six to 11 years of age, as indicated previously for those 12 years-adult. Omalizumab has also been evaluated for efficacy to provide protection from food-driven allergic reactions or to augment oral desensitisation protocols [1-3,5]. In February 2024, it became the first FDA approved drug to reduce the risk of IgE-mediated allergic reactions (including anaphylaxis) to >1 food allergen. | View clinical data
Immuno Disease Comments: Antihistamine approved for CIU.
Clinical Use: Loratidine is used to relieve the symptoms of allergic rhinitis and chronic idiopathic urticaria. | View clinical data


Show »

1. Abdel-Gadir A, Schneider L, Casini A, Charbonnier LM, Little SV, Harrington T, Umetsu DT, Rachid R, Chatila TA. (2018) Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy, 48 (7): 825-836. [PMID:29700872]

2. Asero R. (2017) Disappearance of severe oral allergy syndrome following omalizumab treatment. Eur Ann Allergy Clin Immunol, 49 (3): 143-144. [PMID:28497679]

3. Bedoret D, Singh AK, Shaw V, Hoyte EG, Hamilton R, DeKruyff RH, Schneider LC, Nadeau KC, Umetsu DT. (2012) Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol, 5 (3): 267-76. [PMID:22318492]

4. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol, 108 (2): 184-90. [PMID:11496232]

5. Lieberman JA, Chehade M. (2013) Use of omalizumab in the treatment of food allergy and anaphylaxis. Curr Allergy Asthma Rep, 13 (1): 78-84. [PMID:23065311]